Spoerl Silvia, Wäscher Dagmar, Nagel Stefanie, Peschel Christian, Verbeek Mareike, Götze Katharina, Krackhardt Angela M
3rd Medical Department, Hematology and Oncology, Klinikum rechts der Isar, Technische Universität München, München, Germany.
Transfusion. 2018 Jul;58(7):1772-1780. doi: 10.1111/trf.14644. Epub 2018 May 6.
Cell separators are routinely used to collect CD34 blood stem cells in the context of customized stem cell transplantation procedures. The Spectra Optia (Terumo BCT) is a novel development of the precursor instrument, the Cobe Spectra (Terumo BCT).
In this report, 146 autologous and 42 allogeneic donors undergoing apheresis on the Cobe Spectra using the mononuclear cell (MNC) program 4.7 or on the Spectra Optia using the new continuous mononuclear cell (cMNC) program 11.2 are compared.
Viability of cells and collection efficacy within the apheresis products was comparable for autologous and allogeneic products collected with the MNC or cMNC method. However, we found a reduced duration of the apheresis procedure and lower hematocrit within the apheresis products when using the cMNC in autologous and allogeneic donors. Moreover, allogeneic donors collected substantially more CD34 cells per kilogram of body weight when using the cMNC method. Differences in platelets before and after apheresis were substantially smaller in this cohort when compared to the cohort collected with the MNC method. Neutrophil and platelet engraftment after autologous or allogeneic transplantation with a product collected with the MNC procedure was comparable to a transplantation with a product processed according to the cMNC method.
Comparison of the MNC (Cobe Spectra) and the cMNC (Spectra Optia) methods demonstrated an equal performance and outcome. However, advantages were present using the cMNC method with respect to apheresis duration and hematocrit within the apheresis product (autologous/allogeneic donors) and numbers of CD34 cells collected, especially in allogeneic donors.
在定制化干细胞移植程序中，细胞分离器常用于收集CD34血液干细胞。Spectra Optia（泰尔茂BCT公司）是其前身仪器Cobe Spectra（泰尔茂BCT公司）的新发展型号。
在本报告中，对146例接受自体造血干细胞采集的供者和42例接受异体造血干细胞采集的供者进行了比较，这些供者分别使用Cobe Spectra的单核细胞（MNC）程序4.7进行单采，或使用Spectra Optia的新连续单核细胞（cMNC）程序11.2进行单采。
采用MNC或cMNC方法采集的自体和异体产品，其细胞活力和单采产品中的采集效率相当。然而，我们发现，在自体和异体供者中使用cMNC时，单采程序的持续时间缩短，且单采产品中的血细胞比容降低。此外，使用cMNC方法时，异体供者每千克体重采集的CD34细胞明显更多。与采用MNC方法采集的队列相比，该队列单采前后血小板的差异要小得多。用MNC程序采集的产品进行自体或异体移植后的中性粒细胞和血小板植入情况，与用cMNC方法处理的产品进行移植后的情况相当。
MNC（Cobe Spectra）方法和cMNC（Spectra Optia）方法的比较表明，二者性能和结果相当。然而，使用cMNC方法在单采持续时间、单采产品中的血细胞比容（自体/异体供者）以及收集的CD34细胞数量方面具有优势，尤其是在异体供者中。
